Company News Archive

EpimiRNA FP7 Grant: working to improve lives of patients

Bicoll brings in its medicinal chemistry competence as an active participant of EpimiRNA project. A first novel lead structure preventing seizures in a human tissue model could be provided through the consortium efforts. Furthermore, there are a number of results achieved already such as identification of new microRNAs, that control brain excitability etc. There are …

China Biotech revolution, special edition

China Biotech revolution, special edition: “Bicoll is the first German-Chinese biotech company.” (Dr. Kai Lamottke, Bicoll GmbH, CEO). Those who missed the printed version – order the e-paper in German or Chinese PDF Download (German)

EpimiRNA: 5 years of successful work to reduce the seizures

5 years of collaborative work with 16 partners under the 7th Framework Programme have been finished with the great results and desire to work further on epilepsy. Bicoll small molecule appeared to be reducing the epileptic seizures and miRNA can block epilepsy. A number of other achievements have been done during these 5 years (e.g. …

BioJapan 2018 and Osaka, ジャパン

医薬、医療から研究機器、設備、エネルギーまで!バイオ産業の「今」が集結!  On the 9th of October Bicoll participates in 欧州のライフサイエンス企業との商談会 in Osaka 2018 European Biotech and Pharma Partnering Conference, Osaka 2018 From 10th till 12th of October Bicoll will exhibit under the umbrella of GermanPavilion (Partnering meetings are also available)  @ BioJapan2018 in Yokohama バイオビジネスにおけるアジア最大級のパートナリングイベント

Open position: Research assistant in phytochemistry, Bicoll Shanghai

Research assistant in phytochemistry (f/m) We are looking for highly motivated and global minded graduates who will be part of phytochemistry team of Bicoll in Shanghai (Zhangjiang Hi-Tech Park). We offer the involvement in diverse research projects in discovery of new natural compounds and activities. Job responsibilities Undertake and assist in the completion of experimental …

Bicoll small molecule has anticonvulsant activity in models of epilepsy

The biopharmaceutical company has promising anti-seizure results with their own designed small molecule lead structure in different epilepsy models Planegg / Martinsried (Germany), May 23, 2018 – Epilepsy is a brain disease affecting about 60 million people worldwide. For at least a third of patients current medicines do not control the recurring seizures. Bicoll’s in-house …

Bicoll was selected to participate in a project “Start.Smart.Japan” within the Accelerator programme “GoGlobal” funded by EIT Health

Bicoll prepares its market entry to Japan with the support of two globally experienced European life science clusters BioM and Biocat Planegg / Martinsried (Germany), May 15, 2018 – Bicoll Group was selected for this exclusive training programme, together with nine (9) other European-based companies from five (5) different countries. It will take part in …

HDDC 2018 – International Helmholtz Drug Discovery Conference

Bicoll is taking part and is one of the sponsors of the second international Helmholtz Drug Discovery Conference, April 26-27, 2018 at Helmholtz Zentrum München. Attracting a high-level audience of researchers, the conference will provide a stimulating platform to discuss with academic experts and scientists from biotech and pharmaceutical industries. Topics include innovative screens on …

EU Industry Day 2018

Dr. Kai Lamottke takes part as a speaker at EU Industry Day on the 23d of February. During the talk he points out the way to improve the EU support for SMEs. EU Industry Day update stakeholders on the Commission’s strategic approach to industrial policy and actions to further develop industrial competitiveness in Europe. It is a …

BICOLL NEWS – 2018

Welcome to the 2018 edition of Bicoll News. For those familiar with Bicoll’s previous yearly newsletters, we would like to introduce the good “new-old” style of a snapshot of topics concerning our last year that aims to provide an overview of our services and capabilities. We thank you, our loyal customers, partners and friends for …